$M

Stocks making the biggest moves premarket: Macy's, Meta, Apple, Novartis and more

Macy's (M) reported Q2 revenue beat, raised guidance, shares down 1.6%. Meta (META) rose 1.4% on JPMorgan upgrade. Apple (AAPL) up 1% post-foldable iPhone launch. Novartis (NVS) gained 2% after shareholder called for board overhaul. Copper miners Freeport-McMoRan (FCX) and Southern Copper (SCCO) fell ~7% and 6% respectively. AeroVironment (AVAV) jumped 5% on Q1 earnings beat. American Eagle (AEO) dropped 15% after Q2 sales miss. Navan (NAV) sank 15.4% despite slight earnings beat. Cooper Compani

Original reporting
Published Sep 10, 2026, 1:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 1:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Stocks making the biggest moves premarket: Macy's, Meta, Apple, Novartis and more — source image
Decision brief

The 30-second read

$MBearishMed
01

Why it matters

The article aggregates multiple primary disclosures, providing traders with a snapshot of immediate catalysts across sectors.

02

Market read

Multiple sectors experience notable premarket moves driven by fresh earnings, guidance, and strategic news, offering short-term trading ideas.

03

What to watch

Potential macro backdrop of interest-rate expectations could amplify moves.

Relevance 5/10Novelty 5/10Timing: premarket today

Background

Premarket roundup of the biggest movers, highlighting earnings beats, guidance changes, upgrades, and strategic announcements.

Company-level read

Ticker impact

$MBearishMedium confidence
Context

Macy's reported Q2 revenue beat and raised full-year guidance, but shares slipped 1.6% premarket.

Expected impact

Modest pullback or sideways as market digests mixed signals.

Evidence & confidence

Guidance raise is positive, but EPS miss and share decline suggest caution.

$METABullishMedium confidence
Context

Meta added 1.4% after a JPMorgan upgrade citing AI upside.

Expected impact

Further upside if AI rollout gains traction.

Evidence & confidence

Upgrade reflects analyst optimism on AI initiatives.

$AAPLBullishLow confidence
Context

Apple rose 1% following unveiling of a foldable iPhone, though stock closed slightly lower.

Expected impact

Limited upside pending consumer response.

Evidence & confidence

Initial reaction muted; longer-term impact uncertain.

$NVSNeutralLow confidence
Context

Novartis rose nearly 2% after a major shareholder called for board overhaul.

Expected impact

Potential swing as board changes are discussed.

Evidence & confidence

Shareholder activism without concrete action yet.

$FCXBearishMedium confidence
Context

Freeport-McMoRan tumbled nearly 7% as copper miners fell.

Expected impact

Further downside if copper prices stay low.

Evidence & confidence

Broad copper price decline impacts earnings outlook.

$SCCOBearishMedium confidence
Context

Southern Copper shed more than 6% alongside copper price fall.

Expected impact

Likely continued weakness pending price recovery.

Evidence & confidence

Direct exposure to copper market.

$AVAVBullishMedium confidence
Context

AeroVironment jumped >5% after Q1 results beat estimates.

Expected impact

Potential further upside if momentum holds.

Evidence & confidence

Earnings beat and revenue beat signal growth.

$AEOBearishHigh confidence
Context

American Eagle Outfitters fell >15% after weak comparable sales and lower operating income forecast.

Expected impact

Further decline likely on earnings miss.

Evidence & confidence

Significant miss and lowered guidance.

Market effects

Broad retail and tech sectors show mixed earnings and guidance impacts; copper sector under pressure.

US premarket activity reflects earnings and guidance across multiple sectors.

Novartis governance news adds European market nuance.

Counterpoint

Some stocks may be oversold despite earnings beats, offering buying opportunities.

Key entities

  • Macy's

    Retail department store

  • Meta Platforms

    Social media and AI

  • Apple

    Technology hardware

  • Novartis

    Pharmaceuticals

  • Freeport-McMoRan

    Copper miner

Related articles

$RDDTMed

Reddit Drops 4% Despite User Growth; Meta Platforms Holds Steady, Snap Rises 1%

Reddit (RDDT) fell 4% to $156.49 despite reporting 18% user growth and 61% revenue growth to $805M. Meta (META) was flat, while Snap (SNAP) rose 1%. Reddit's international user base grew 28%, with revenue up 84%. The company's adjusted EBITDA doubled to $343M, and free cash flow reached $261M. Investors seem focused on valuation and future growth prospects.

$ENBMed

Tuesday’s analyst upgrades and downgrades

National Bank Financial upgraded Enbridge (ENB) to 'outperform' citing its North American oil production growth and recent acquisitions. Analyst Patrick Kenny raised the target price to $82. TD Cowen upgraded TC Energy (TRP) to 'buy' seeing a 16% pullback as an attractive entry point. National Bank initiated coverage of MDA Space (MDA) with an 'outperform' rating, highlighting its space investment growth potential.

$AAPLLow

iOS 27 is out now — Siri AI arrives for US and UK, but the EU gets left behind

Apple released iOS 27, featuring Siri AI, which integrates app data for context-aware responses. US and UK users have access, but EU users are blocked due to regulatory issues. Siri AI requires compatible hardware and English language settings. The update also includes interface redesigns, AI photo tools, and performance improvements. Apple claims app launch speeds improve by up to 30%.

$NVSLowAI 8/10

Back to Back Heart Drug Failures at Novartis and Novo Nordisk Undercut Two Leading Theories of Cardiovascular Risk

Novartis' pelacarsen and Novo Nordisk's ziltivekimab failed in Phase 3 trials, testing different cardiovascular risk theories. Both drugs did not reduce cardiovascular events despite lowering targets. Novartis reported pelacarsen's Lp(a)HORIZON trial results, while Novo Nordisk halted ziltivekimab's HERMES and ATHENA trials. Analysts estimated pelacarsen's peak sales at $4B-$6B. Both companies have other trials ongoing.